Bevacizumab effect in diabetic macular edema sustained at two years

NEW YORK (Reuters Health) - A study conducted at Moorfields Eye Hospital in London, UK, finds that the benefits seen at one year with bevacizumab treatment of macular edema are sustained at two years, with comparatively few intravitreal injections.

Full Story →